Skip to main content

Table 1 TKIs for imatinib-resistant GIST

From: Recent advances and novel agents for gastrointestinal stromal tumor (GIST)

Study Drug Disease Clinical Trial Number of patients Results Status Reference
Sunitinib Imatinib-resistant Phase 3 312 TTP 27 weeks FDA Approved. On NCCN guidelines. [38]
Sorafenib Imatinib- and Sunitinib resistant Phase 2 38 ORR 68% On NCCN guidelines. [39]
Nilotinib Imatinib- and Sunitinib resistant Phase 3 ( ENEST g3) 248 No difference in PFS or OS Further trials [40]
Sorafenib Imatinib- and Sunitinib resistant Phase 2 41 ORR 37.6% On NCCN guidelines. [41]
Dasatinib Imatinib- and Sunitinib resistant Phase 1 47 PR - 32% Further trials [42]
  1. Abbreviations: TTP time to progression; ORR overall response rate; PR partial response.